Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Genoway S.A. is a specialized biotechnology company that develops and markets genetically modified animal models for research purposes. Its primary function is to provide customized and innovative solutions for pharmaceutical companies, academic institutions, and governmental research bodies to facilitate drug discovery and development processes. Genoway's offerings include genetically-tailored mouse, rat, and other animal models, which are integral in understanding human diseases and testing new treatments. The company impacts several sectors, notably the pharmaceutical, healthcare, and academic research fields. By enabling precise genetic modifications, Genoway plays a critical role in the acceleration of biomedical research, ultimately contributing to the advancement of medical knowledge and therapies. Headquartered in France, Genoway is considered a key player within the biotechnology market, recognized for its technological expertise and contribution to the enhancement of scientific studies.
Operating margin is thin at 3.19%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 5.0% YoY. Margins deteriorated 3.2pp alongside, both lines moving the wrong way.
Free cash flow declined 513% versus the prior year, cash generation momentum has weakened. ROIC dropped from 5.74% to 2.13%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (TTM)
€21M
▼ -5.0% YoY
Net Income (TTM)
€928K
▼ -49.3% YoY
Op. Margin
3.19%
▼ -3.2pp YoY
ROIC
2.13%
▼ -3.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€12M
▼ -512.5% YoY
Op. Cash Flow (TTM)
-€3M
▼ -192.2% YoY
Net Debt
€7M
Cash & Equiv.
€7M
3Y CAGR: +7.1%
Continue Research